Chris Culberson

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

39

H-Index

1

About

Chris Culberson is a researcher whose work has centered on the discovery and characterization of metabotropic glutamate receptor (mGluR) ligands, with a particular focus on developing novel antagonists for neurological applications. His most-cited contribution, "Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system" (2003, 39 citations), exemplifies his expertise in merging advanced pharmacological screening methodologies with targeted drug discovery. This work not only identified key molecular tools for studying mGluR function but also demonstrated the power of automation in accelerating the pace of receptor-targeted research. Culberson’s contributions have provided foundational insights into the modulation of glutamatergic signaling, which is critical for understanding disorders such as anxiety, schizophrenia, and chronic pain. His approach—combining rigorous biochemical assays with high-throughput technologies—has influenced subsequent studies in both academic and industrial settings, making his work a valuable resource for researchers exploring the therapeutic potential of mGluR antagonists.

Research Focus

Key Achievements

1
H-Index
1
Papers
39
Total Citations
39
Avg Citations/Paper
🏆 Most Cited Paper
Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system
39 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago